Hikma Pharmaceuticals PLC (LON:HIK)
1,885.00
-6.00 (-0.32%)
Apr 17, 2025, 4:35 PM BST
Hikma Pharmaceuticals Employees
Hikma Pharmaceuticals had 9,500 employees as of December 31, 2024. The number of employees increased by 400 or 4.40% compared to the previous year.
Employees
9,500
Change (1Y)
400
Growth (1Y)
4.40%
Revenue / Employee
262.92K GBP
Profits / Employee
30.19K GBP
Market Cap
4.16B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,315 |
Genus | 3,500 |
Hikma Pharmaceuticals News
- 1 day ago - Hikma acquires Novugen's FDA-approved ANDA for trametinib - PRNewsWire
- 7 weeks ago - Hikma Pharmaceuticals PLC (HKMPF) Q4 2024 Earnings Call Pre-Recorded (Transcript) - Seeking Alpha
- 7 weeks ago - Hikma Pharmaceuticals reports FY results - Seeking Alpha
- 3 months ago - Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - Benzinga
- 3 months ago - Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - PRNewsWire
- 8 months ago - Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices - Benzinga
- 8 months ago - Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day - PRNewsWire
- 8 months ago - KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months - Benzinga